Aim: A point mutation of apolipoprotein A-, V156E, is naturally occurring and is found in Oita, Japan. V156E of apoA-(apoA-oita) shows unique structural and functional properties and more potent antioxidant activity against copper-mediated low-density lipoprotein (LDL) oxidation in vitro. 
pies, such as the intravenous infusion of apoA-/phospholipid, result in an anti-atherosclerotic effect with stimulation of cholesterol efflux, and/or an atheroma regression effect in mice 3) , rabbits 4) , and humans 5, 6) . With the availability of such promising results, it has become widely accepted that apoA-and HDL constitute an emerging therapeutic target for coronary artery disease, a process referred to as HDL therapy
Introduction
Evidence has accumulated to support the notion that high-density lipoprotein (HDL) has atheroprotective effects by enhancing reverse cholesterol transport 1) . Apolipoprotein (apo) A-is a major protein component of HDL and possesses strong anti-oxidant and anti-inflammatory activities 2) tial in a series of in vivo experiments in animals [9] [10] [11] and humans 12, 13) . Among these reports, the Nissen group 12) published clinical data suggesting that blood infusion of the phospholipid-apoA-Milano complex generated significant regression activity, up to 4% above the baseline, as measured by intravascular ultrasound, whereas the placebo group showed no reduction in atheroma volume. These studies indicate the possible existence of a strong positive correlation between lesion regression activity, anti-oxidant activity, and anti-inflammatory activity.
In a previous report, V156E of apoA-(apoA-oita) was shown to have unique structural and functional properties in vitro 14, 15) . The homozygous carrier of apoA-oita is a 67-year-old Japanese man who resides in Oita, Japan, with a body mass index of 27.5 kg/m 2 and markedly low serum apoA-and HDL-cholesterol levels 16) . Although he has smoked 50 cigarettes per day for 50 years, he does not show tonsillar hypertrophy, tendinous xanthomata, hepatosplenomegaly, or peripheral neuropathy. Although the proband also presented with clinical features of arteriosclerosis, he had other coronary risk factors apart from his apoA-deficiency, such as age, smoking, and obesity; however, the proband's elder brother, who was homozygous for V156E, did not have any symptoms suggestive of coronary artery diseases 16) . Purified recombinant V156E protein in a lipidfree state exhibits slightly different conformational changes, but is more stable and quite resistant to selfassociation compared to the controls, apoA- 14) and V156K 17) . V156E-rHDL is resistant to particle rearrangement in the presence of LDL 14) and the addition of apoA- 15) , while V156K-rHDL is not resistant to particle rearrangement. These results indicate that the V156E mutant displays a different structural "hinge" or mobile region of apoA-, which is involved in HDL structural rearrangements. It is well-established that displacement of apoA-helices resulting from interaction with LDL and apoA-could weaken the antiatherogenic function of HDL containing apoA-. Additionally, a recent crystallographic study revealed that Val156, Leu159, and P165 form a hydrophobic core and are important in the functioning of apoA- 18) . From these unique properties of V156E, it is possible to speculate that V156E might have putative anti-atherosclerotic activity in the circulation.
In this study, to test the feasibility of HDL therapy using V156E, the anti-atherosclerotic effects of V156E were assessed in vitro and in vivo using THP-1 cells and apo-E deficient mice, respectively, to verify lesion regression activity, anti-oxidant activity, and anti-inflammatory activity.
Methods

Apolipoprotein Production and rHDL Synthesis
Wild-type proapoA-and the V156E variant were expressed and purified as described previously using a polymerase chain reaction based on a site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) with appropriately designed primers 14) . Reconstituted HDL (rHDL) was prepared via sodium cholate dialysis, using initial molar ratios of POPC:cholesterol:apoA-:sodium cholate of 95:5:1:150 19) . After synthesis, the removal and quantification of endotoxin was conducted, as previously described 20) .
Antioxidant Activity Against Copper-Mediated LDL Oxidation
In a 500 L reaction volume, fresh human LDL (50 g protein) was incubated with 300 nM (final concentration) of either WT-rHDL or V156E-rHDL in the presence of 10 M (final concentration) of CuSO4 for up to 2 hr. During incubation, the number of conjugated dienes formed was monitored at 234 nm at 24.5 21) using a DU800 spectrophotometer (Beckman-Coulter, Fullerton, CA, USA) equipped with a MultiTemp thermocirculator (Amersham, Uppsala, Sweden).
LDL Oxidation
LDL (1.019 d 1.063) was isolated by ultracentrifugation from healthy human plasma using a Himac CP90 (Hitachi, Tokyo, Japan), and then dialyzed against PBS.
Oxidized LDL (oxLDL) was produced by incubation with CuSO4 (final concentration, 10 M) for 4 hr at 37 and then filtered (0.2 m) prior to use. A thiobarbituric acid-reacting substance (TBARS) assay was then used to evaluate the oxidation extent of oxLDL 22) .
Measurement of Oxidized LDL Accumulation in THP-1 Cells
THP-1 cells, a human monocyte cell line, were obtained from the American Type Culture Collection (ATCC; #TIB-202 TM ; Manassas, VA, USA) and maintained in RPMI 1640 medium (Hyclone) supplemented with 10% fetal bovine serum (FBS) until needed. Cells that had undergone no more than 20 passages were incubated in medium containing phorbol 12-myristate 13-acetate (PMA; final concentration, 150 nM) in 12-well plates (8 10 5 cells per well) for 24 − 48 hours at 37 in a humidified incubator (5% CO2, 95% air) to induce differentiation into macrophages 23) . The differentiated and adherent macro-phages were then rinsed with warm PBS and incubated with 800 L fresh RPMI 1640 medium containing 1% FBS, 100 L oxLDL (1 mg protein/mL in PBS; final concentraion 0.2 M), and 100 L PBS or each rHDL (1.4 mg protein/mL in PBS; final concentration, 5 M) for 48 hours at 37 in a humidified incubator. After incubation, the cells were washed with PBS 3 times, and then fixed in 4% paraformaldehyde for 10 min. Next, the fixed cells were rinsed with 100% polypropylene glycol, stained with oil-red O staining solution (0.67%), and then washed with distilled water. THP-1 macrophage-derived foam cells were then observed and photographed using a Nikon Eclipse TE2000 microscope (Tokyo, Japan) at 600x magnification. The cell medium was then analyzed by the TBARS assay to compare the change in the level of oxidized species among groups. 3 H]-CE-LDL (1 mg/mL apoB, 0.2 M) was administered to the differentiated THP-1 cells (12-well plates) in the presence of WTrHDL (final concentration, 5 M), V156E-rHDL (final concentration, 5 M), or PBS. After a 48-hour incubation period, the cell medium was collected and the cells were rinsed in PBS 3 times. The amount of isotope in THP-1 cells was measured by scintillation counting after cell lysis by treatment with 1 mL of 0.5 M NaOH.
Reassembly of
Measurement of Cholesterol Delivery into HepG2 Cells
Hepatic carcinoma cells (HepG2) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, and 1% (v/v) penicillin/streptomycin. Cells were incubated in a chamber with an air-humidified atmosphere containing 5% CO2 at 37 .
An aliquot of WT-and V156E-rHDL containing radiolabeled cholesterol (2 Ci of [
14 C]-cholesterol/mg of apoA-) was added to 12-well plates (4 10 5 cell/ well) of HepG2 cells at a final concentration of 25 M in the absence of acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor in order to allow for cholesterol esterification. After the designated incubation time, the cell medium was aliqouted and the cells were rinsed with 1 mL PBS 3 times. The amount of isotope in HepG2 cells was measured by scintillation counting after cell lysis by treatment with 1 mL of 0.5 M NaOH.
Apo-E Deficient Mice
Male apo-E deficient mice on a C57BL/6J (5 weeksold, apoe tm1Unc ) background were purchased from Jackson Laboratories (Bar Harbor, MA, USA), and maintained on a chow diet (CRF-1, Oriental Yeast, Tokyo, Japan). After 1-week acclimation to the chow diet, a Western diet (0.15% cholesterol/15% lard/ 0.05% sodium cholate) was provided for 12 weeks ad libitum with free access to water. The mice were then randomly divided into 3 groups and treated via the tail vein with rHDL in 0.4 mL of phosphate-buffered saline (PBS), as described in Table 1 . All procedures were approved by the Committee of Animals for Research of Yeungnam University (Gyeongsan, Korea).
Sample Collection and Analysis
Twenty-four hours after injection, a small volume of blood (0.1 mL) was collected from the retroorbital plexus via heparinized microhematocrit capillaries (Sigma), and the mice were bled until death 48 hours post-injection. Serum total cholesterol (TC), HDL-cholesterol (HDL-C), and triglyceride (TG) con- centrations were determined with an automatic blood analyzer (Hitachi 7020; Tokyo, Japan). Serum TC concentrations were again verified via manual determination using a commercially available assay kit (Wako Chemical, Tokyo, Japan). The residual quantities of injected apoA-in rHDL were determined using an apoA-AUTO • N • Daiichi kit, which contained human apoA-antibody (Daiichi Pure Chemicals, Tokyo, Japan). This kit detects human apoA-and proapoA-, but not mouse apoA-. Serum lipid hydroperoxide (LPO) was determined colorimetrically by a commercial kit (Cat# 437639; Calbiochem, San Diego, CA, USA) according to the manufacturer's recommendations.
Fatty Streak Lesion Analysis
Aortic lesion formation was assessed via the method described by Paigen et al. 25) with some slight modifications 26) . After the mice were bled to death, their hearts were perfused via the left ventricle with 30 mL of 4% paraformaldehyde, and fixed for at least 24 hours. The isolated upper heart/aortic sinus was then embedded in Tissue-Tek OCT compound (Fisher Scientific, Pittsburg, PA, USA) and frozen. The frozen tissue blocks were then positioned in a cryotome model AS620 (Shandon, Pittsburg, PA, USA), and 10-m serial sections of the ascending aorta were collected on 3-aminopropyltriethoxysilane-coated slides until the aortic sinus appeared. The sectioned slides were stained with Oil Red-O and hematoxylin in order to visualize any fatty streak lesions, according to standard protocols. The mean size of the lipid-stained area was calculated and quantified via computer-assisted morphometry.
Immunohistochemical lesion analysis was conducted using a commercially available kit (Vector Labs, Peterborough, UK) using anti-mouse macrophage antibody (MOMA-2 and MCA519; Serotec). To visualize the macrophages detected in the lesion area, fluorescence-labeled secondary antibody (Cy2-conjugatedanti-IgG) was used and observed under confocal microscopy (LSM510 meta; Zeiss).
Cholesteryl Ester Conversion Assay
Cholesteryl ester conversion was conducted via lecithin:cholesterol acyltransferase (LCAT) assays, as previously described 19) ; 30 L of HDL3 (2 mg/mL protein) was utilized as the enzyme source. ApoA--rHDL containing radiolabeled cholesterol (1 Ci of [
14 C]-4-cholesterol/69 g of cholesterol/1 mg of apoA-) was utilized as a substrate. Discoidal rHDL was prepared via sodium cholate dialysis using initial molar ratios of palmitoyloleoyl phosphatidylcholine (POPC):cholesterol:apoA-:sodium cholate at 95:5:1:150. The reaction was initiated via the addition of mouse serum, and the mixture was incubated for 1 hour at 37 . The esterified cholesterol and free cholesterol were separated via thin-layer chromatography. Activity was expressed as the percent conversion rate (%) of cholesteryl ester from free cholesterol.
Paraoxonase Assay
Paraoxonase-1 (PON) activity toward paraoxon was measured after the reaction of paraoxon hydrolysis in p-nitrophenol and diethylphosphate catalyzed by the enzyme 27) . PON-1 activity was determined from the initial velocity of p-nitrophenol production at 37 and 
Ferric Reducing Ability of Serum Assay
The ferric reducing ability of serum (FRAS) was determined, as described by Benzie and Strain 28) , because the FRAS assay is known to be a rapid and reproducible method for determining the molar concentration of the antioxidant present. FRAS reagents were freshly prepared by mixing 25 mL of 0.2 M acetate buffer (pH 3.6), with 2.5 mL of 10 mM 2,4,6, tripyridyl-s-triazine (TPTZ, Sigma #T1253), and 2.5 mL of 20 mM FeCl3 6H2O solution. The antioxidant activities of the sera were then estimated from the increase in absorbance induced by the generated ferrous ions. Freshly prepared FRAS reagent (300 L) was mixed with 10 L serum and 30 L water. Absorbance readings were obtained at 593 nm every 20 seconds over a 10-minute period.
Western Blot Analysis
Anti-human LCAT antibody was purchased from Abcam (Cat# ab786; Cambridge, UK. Relative band intensities were compared by band scanning using a Gel Doc ® XR (Bio-Rad, Hercules, CA, USA) with Quantity One software, version 4.5.2.
Statistical Analysis
All data are expressed as the mean S.D. Data were evaluated by one-way analysis of variance (ANOVA) using an SPSS program, version 14.0 (SPSS, Inc., Chicago, IL, USA), and differences between the means were assessed using Duncan's multiple-range test. Sta-tistical significance was defined as p 0.05.
Miscellaneous
Serum interleukin (IL)-6 levels in individual mice were measured in duplicate with an enzyme-linked immunosorbent assay kit (MS6000B Quantikine kit; R&D Systems). Protein concentrations were determined via a Lowry protein assay, modified as described by Markwell et al. 29) , or using the Bradford assay reagent, with bovine serum albumin used as a standard. The removal of endotoxin from POPC-rHDLs was verified by testing with a limulus amebocyte lysate kit (BioWhittacker #50-647U; Walkersville, MD, USA), in accordance with the manufacturer's instructions.
Results
Protein Purification and rHDL Synthesis
The purity of WT-proapoA-(29 kDa) and V156E (29 kDa) was at least 95% from SDS-PAGE and densitometric analysis, as shown in Fig. 1A . In the rHDL preparation, a molar ratio of 95:5:1 (POPC:cholesterol: apoA-) with WT resulted in a 97 − 98 Å POPC-rHDL, as in previous reports 14, 15) ; however, rHDL synthesis with V156E revealed larger rHDL (approximately 110 Å in diameter) using the same molar ratio as shown in Fig. 1B . The rHDLs showed a similar range of residual endotoxin level (approximately 2.9 − 3.1 EU/mL) based on endotoxin quantification using the limulus amebocyte lysate kit.
V156E-rHDL Showed More Potent Antioxidant Activity In Vitro
During 120-minute incubation, V156E-rHDL showed the least production of the conjugate diene, from 0.514 to 0.602 (Abs234), while WT-rHDL increased from 0.519 to 1.537 (Abs234) at the same protein concentration (final concentration, 300 nM), as shown in Fig. 2 . This result indicates that V156E has more potent antioxidant activity against copper-mediated LDL oxidation than WT in a time-dependent manner.
To test further antioxidant activity in macrophage cells, differentiated THP-1 cells were treated with oxLDL (final concentration, 0.2 M) in the presence of V156E-rHDL or WT-rHDL. After 48-hour incubation, THP-1 cells were stained with oil red O to evaluate the degree of lipid or LDL accumulation in the cells. As shown in the photographs in Fig. 3 , the strongest red color intensity was observed in PBStreated cells, while the intensity was much decreased in V156E-rHDL-treated cells. This result correlated well with the results of a TBARS assay of the culture The reaction was initiated by the addition of 10 M CuSO4 to the reaction mixture (500 L), which contained fresh LDL (50 g protein in PBS) and 300 nM (final concentration) of each rHDL. Data were averaged from three independent assays per group. Bar represents standard deviation.
media. As shown in Fig. 3 , media derived from V156E-rHDL-treated cells showed the least MDA than media used to culture PBS-treated cells, although media derived from WT-rHDL-treated cells contained less MDA than PBS-treated cells. Taken together, these findings suggest that V156E-rHDL has the potential to inhibit further oxidation of LDL in culture media and the cellular accumulation of oxLDL in macrophages was superior to that of WT-rHDL.
V156E-rHDL Suppressed Accumulation of [ 3 H]-Sterol in THP-1 Cells
In the presence of WT-rHDL or V156E-rHDL, the cellular accumulation of isotope derived from [ 3 H]-CE was lower than that of PBS-treated cells. As shown in Fig. 4A , WT-rHDL-treated cells showed a 26% decrease in [ 3 H]-sterol accumulation, while V156E-rHDL showed a 53% decrease compared to that of PBS treatment after 24-hour incubation. This result is in good agreement with the report from the Horiuchi group 30) which showed that DMPC/apoA-reduces ligand activity of ox-LDL to accumulate CE in mouse peritoneal macrophages.
V156E-rHDL Facilitated Cholesterol Delivery into HepG2 Cells
In order to facilitate the excretion of cholesterol from the circulation, the major beneficial role of HDL involves the delivery of cholesterol into hepatic tissues from peripheral cells via reverse cholesterol transport 31) . In order to evaluate this cholesterol delivery activity, [ 14 C]-cholesterol was used as a detection marker located in the core of each rHDL. After treatment of HepG2 cells with each radiolabeled rHDL, V156E-rHDL exhibited superior delivery efficiency to WT-rHDL in a time-dependent manner, as shown in Fig. 4B . During the incubation period, V156E-rHDL had 1.5-fold enhanced cholesterol delivery activity Differentiated macrophages were incubated with 50 L oxLDL (1 mg/mL), 50 L rHDL (1.4 mg/mL), and 400 L RPMI 1640 media. The extent of cellular uptake of lipids or LDL in macrophages was then compared by Oil Red-O staining, as described in the text. The cells were then photographed using a Nikon Eclipse TE2000 microscope at 600x magnification. The cell medium was analyzed by the TBARS assay to determine the production of the oxidized species. Malondialdehyde (MDA) was used as a standard and the extent of oxidation was expressed as the MDA concentration (arbitrary unit, AU).
compared to WT-rHDL (Fig. 4B) .
V156E-rHDL Infusion Improved the Serum Lipid Profile
After 12 weeks on a Western diet, all mice had high levels of serum TC, with an average of 1,285 and 1,253 mg/dL for WT-rHDL and V156E-rHDL groups, respectively. At 24 hours, serum TC was significantly decreased (approximately 23%) from the initial value after V156E-rHDL infusion, while it had decreased approximately 8% in the WT-rHDL infusion ( Table 2) . The amount of HDL-C did not change during 48 hours in both groups. Twenty-four hours after the infusion of rHDL, the serum TG level was increased by 2.0-and 1.3-fold for WT-rHDL and V156E-rHDL, respectively, compared to 0 hours; however, the serum TG level 48 hours after blood infusion was significantly decreased by approximately 42% compared to 24 hours after blood infusion in both groups. Similarly, Marchesi et al. 32) reported the elevation of serum TG as a result of ETC-216 (POPC/R173C apoAcomplex) in a rabbit model, although the mechanism was not fully elucidated. In the V156E-rHDL injection, the concentration of TG decreased from 136 25 mg/dL 24 hours post-injection to 78 11 mg/dL at 48 hours. ELISA-based immunoquantification of apoArevealed that V156E-rHDL was more detectable than WT-rHDL in mouse sera, as shown in Table 2 . Twentyfour hours post-injection, the amount of proapoAdetected in V156E-rHDL-injected mice was 9 2 mg/ dL, while WT-rHDL was 2 1 mg/dL. Forty-eight hours post-injection, V156E-rHDL-injected mice showed 4 2 mg/dL of detected apoA-, while almost no apoA-was detected in WT-rHDL-injected mice.
V156E-rHDL Revealed Enhanced Anti-Inflammatory Effect
V156E-rHDL-infused sera had lower IL-6 levels at both 24 and 48 hours than the WT-rHDL-infused group. The serum LPO level decreased around 38% in the V156E-rHDL group (2.1 nmol/mL) compared to WT-rHDL (3.4 nmol/mL), indicating less production of oxidized species in the V156E group. These results indicate that V156E-rHDL showed more antiinflammatory properties than WT-rHDL, and did not provoke an inflammatory process, including lower serum IL-6 and LPO levels.
Atherosclerotic Lesions were Reduced More in the V156E-rHDL Group
As shown in Fig. 5 , apo-E-deficient mice exhibited a thick fatty streak lesion following consumption of a Western diet for 12 weeks; the PBS-treated group showed a 369,742 56,451 m 2 lipid-stained area. Comparison of the thickness at the same position showed that the V156E-rHDL group had a reduced lipid-stained area (221,850 31,050 m 2 ), whereas the area in the WT-rHDL group was larger (272,130 44,000 m 2 ), as shown in Fig. 5 . The lipid-stained area was decreased approximately 18% by V156E-rHDL injection compared to WT-rHDL (Fig. 5) . The MOMA-2-stained region in the fatty streak lesion was also reduced in the V156E-rHDL group (11 2%) compared to the WT-rHDL group (18 3%), while the Table 2 . Serum profiles of apo-E deficient mice after blood infusion PBS group was 25 3%, as shown in Fig. 6 . These results indicate that V156E-rHDL exhibited more potent regression activity than WT-rHDL, including a reduction in the lipid-stained lesion area and macrophage accumulation within the lesion.
Serum LCAT Activity was Increased More in the V156E-rHDL Group
As shown in Fig. 7A , WT-rHDL-injected mice showed 6 − 8% CE-conversion activity at 24 and 48 hours, while V156E-rHDL-injected mice showed approximately 12% CE-conversion activity. In addition to activity, protein expression levels were also increased in V156E-rHDL-injected mouse sera (Fig. 7A) after 24-and 48-hour blood infusion, as determined by immuno-detection. The V156E-HDL group showed 2.8-and 2.5-fold darker band intensities 24 and 48 hours post-injection, respectively, than the WT-rHDL group.
Since it has been reported by the Forte group that apo-E deficient mice have minimal LCAT activity 31) , in which approximately 50% of LCAT activity was diminished in apoE-knockout mice, rHDL injection might enhance serum LCAT activity and expression.
Serum Paraoxonase and Antioxidant Activity
Twenty-four and 48 hours post-injection, the V156E-rHDL group had approximately 100 4 U/L serum paraoxonase activity, while WT-rHDL-injected mice had approximately 80 3 U/L serum paraoxonase activity (Fig. 7B) . This result indicates that the V156E-rHDL group had approximately 25% enhanced paraoxonase activity.
The FRAS assay is known to be a rapid and reproducible method for determining the molar concentration of the antioxidant present 28) . The FRAS assay revealed that the V156E-rHDL group had approxi- mately 20% increased absorbance compared to the WT-rHDL group during 10-minute incubation. The WT-rHDL group showed decreased FRAS activity at 48 hours compared to 24 hours, whereas the V156E-rHDL group showed the same degree of FRAS activity at 24 and 48 hours. These res ults are good correlations because PON and LCAT activity is involved in maintaining serum antioxidant activity 34) .
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Discussion
HDL therapy using artificially synthesized HDL has emerged recently as a new therapeutic approach to treat coronary artery disease. HDL therapy is basically supported by the following factors associated with the beneficial effects of HDL: antioxidant activity against LDL-oxidation; anti-inflammatory activity; antithrombotic activity; and profibrinolytic effects. It is well-recognized that the therapeutic effect of HDL mainly originates from its protein constituent, especially in apoA- 7) . The Shah group reported that the phospholipid R173C-apoA-complex showed potent anti-atherosclerotic activity regardless of DPPC and POPC 9, 35) . As with R173C, V156E-apoA-is a naturally occurring mutant and was described first by Huang et al. 16) .
In the lipid-bound state, especially in the POPCrHDL state, V156E showed more alpha-helix content and formed a larger rHDL (110 Å) than control apoA-(97 Å), as shown in Fig. 1B . V156E-rHDL was resistant to particle rearrangement in the presence of LDL 14) and the addition of apoA- 15) . The current report is in good agreement with the previous observation; blood infused with V156E-rHDL was detected to a greater extent than WT-rHDL in mouse sera ( Table 2) 24 and 48 hours post-injection. Although the exact mechanism remains to be elucidated, this result suggests that V156E-rHDL might be more resistant to protein degradation, with a putative interaction with LDL or displacement of apoA-by the addition of the apoA-helix domain into apoAhelix. Similarly, Durbin and Jonas 36) proposed that 4 helices of apoA-between residues 99 and 187 are displaced from phospholipid acyl chains by insertion of 4 helical domains of apoA-. This result is in good agreement with our previous observation that V156E-rHDL was resistant to particle rearrangement in the presence of LDL and showed different cleavage patterns by mild proteolysis 14, 15) . Table 2 , serum TG and IL-6 levels were increased by rHDL infusion 24 hours post-injection, compared to PBS infusion. The injection of foreign protein, purified from the E.coli expression system, might increase serum TG and IL-6 values since residual endotoxin in protein could trigger an inflammatory cascade; however, apoA--rHDL can also neutralize endotoxin and attenuate organ injury, as reported by McDonald et al. 37) . Therefore, this result can be interpreted that V156E-rHDL is superior to WT-rHDL in the neutralization of endotoxic shock, rather than WT-rHDL having a cytotoxic effect. Serum TG was decreased to a greater degree in the V156E-rHDL group 48 hours post-infusion.
As shown in
Regarding the increase in serum TG, we recently reported a direct relationship between the increase in serum TG and the levels of acute inflammatory process markers, such as IL-6, and a decrease of HDL-C in the oliguric phase of patients with hemorrhagic fever renal syndrome (HFRS) 38) . Many studies have suggested that TG-rich lipoproteins are proatherogenic 39) . The presence of increased TG in lipoprotein is in good agreement with the results of previous studies indicating that TG levels are an important and independent predictor of CHD and stroke 40) . Although rHDL inhibited the cellular uptake of [ 3 H]-CE in THP-1 cells (Fig. 4A) In contrast, an interesting finding of the current report was that V156E-rHDL-injected mice showed enhanced LCAT activity. Although V156E-rHDL was a poor substrate in the in vitro assay 14) , the LCAT source in this assay was human serum or HDL3; therefore, it is possible to speculate that mouse serum LCAT is more activated by infused V156E-rHDL because it had sufficient antioxidant capacity, as shown in Fig. 2,  3 , and 7. Enhanced LCAT activity might directly contribute to anti-atherosclerotic activity for regression. Furthermore, the highest increases of serum LCAT (Fig. 7A) and PON (Fig. 7B ) activity in the V156E group also correlated well with the enhanced in vivo antioxidant activity observed in the FRAS assay (Fig. 7C) , indicating that the better antioxidant activity of the V156E-rHDL group might be due, at least in part, to stronger in vivo LCAT and PON activity.
In conclusion, V156E-rHDL showed potent in vitro antioxidant ability and has several beneficial physiologic effects, including antioxidant and anti-atherosclerotic activities in apo-E-deficient mouse sera. V156E-rHDL had much larger particles than WTrHDL in vitro and more remained in mouse sera 48 hours post-injection. Twenty-four and 48 hours postinjection, the V156E-rHDL group showed decreased serum TC, IL-6, and LPO levels compared to the WT-rHDL group. The current finding corroborates that substitution of Val156 with a positively or negatively charged amino acid, Lys or Glu, respectively, could improve the function and structure of HDL, which might increase the therapeutic potential.
